(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
(Nasdaq Global Market) |
ZENTALIS PHARMACEUTICALS, INC. | ||||||||||||||
Date: November 17, 2021 | By: | /s/ Anthony Y. Sun, M.D. | ||||||||||||
Anthony Y. Sun, M.D. | ||||||||||||||
President and Chief Executive Officer |
Cover |
Nov. 10, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Nov. 17, 2021 |
Entity Registrant Name | ZENTALIS PHARMACEUTICALS, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39263 |
Entity Tax Identification Number | 82-3607803 |
Entity Address, Address Line One | 530 Seventh Avenue |
Entity Address, Address Line Two | Suite 2201 |
Entity Address, City or Town | New York |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 10018 |
City Area Code | 212) |
Local Phone Number | 433-3791 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | ZNTL |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001725160 |
Amendment Flag | false |
&UL4$L! M A0#% @ ^HEQ4Y>*NQS $P( L ( !BP\ %]R M96QS+RYR96QS4$L! A0#% @ ^HEQ4ZK$(A8S 0 (@( \ M ( !=! 'AL+W=O7!E &UL4$L%!@ ) D /@( ,4 $ $! end